GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Cash Flow from Financing
中文

Recce Pharmaceuticals (ASX:RCE) Cash Flow from Financing : A$11.74 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Recce Pharmaceuticals received A$10.59 Mil more from issuing new shares than it paid to buy back shares. It spent A$1.48 Mil paying down its debt. It paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received A$0.00 Mil from paying cash dividends to shareholders. It received A$0.00 Mil on other financial activities. In all, Recce Pharmaceuticals earned A$9.11 Mil on financial activities for the six months ended in Dec. 2023.


Recce Pharmaceuticals Cash Flow from Financing Historical Data

The historical data trend for Recce Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Cash Flow from Financing Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Financing
Get a 7-Day Free Trial 2.43 6.09 26.12 -0.24 2.71

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.07 2.63 9.11

Recce Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Recce Pharmaceuticals's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Recce Pharmaceuticals's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$11.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recce Pharmaceuticals  (ASX:RCE) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Recce Pharmaceuticals's issuance of stock for the six months ended in Dec. 2023 was A$11.15 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Recce Pharmaceuticals's repurchase of stock for the six months ended in Dec. 2023 was A$-0.56 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Recce Pharmaceuticals's net issuance of debt for the six months ended in Dec. 2023 was A$-1.48 Mil. Recce Pharmaceuticals spent A$1.48 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Recce Pharmaceuticals's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. Recce Pharmaceuticals paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Recce Pharmaceuticals's cash flow for dividends for the six months ended in Dec. 2023 was A$0.00 Mil. Recce Pharmaceuticals received A$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Recce Pharmaceuticals's other financing for the six months ended in Dec. 2023 was A$0.00 Mil. Recce Pharmaceuticals received A$0.00 Mil on other financial activities.


Recce Pharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Recce Pharmaceuticals (ASX:RCE) Business Description

Traded in Other Exchanges
Address
180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines